Cannabis finance news

Cannabis seeing ‘explosive growth’ but data reveals sales dogfight beyond the market leaders

by Steve Jones February 1, 2024February 1, 2024

Retail pharmacy sales of medicinal cannabis hit at least A$165 million in 2023, latest figures from […]

Cann Group delivers ‘modest’ growth as imports continue to frustrate

by Steve Jones February 1, 2024February 1, 2024

‘Significant’ probe underway as Epsilon creditors raise ‘various matters’

by Steve Jones January 31, 2024July 11, 2024

LGP reports sales downturn but predicts a ‘re-rating’ of Australian firms amid US rescheduling report

by Steve Jones January 31, 2024July 11, 2024

Shareholders reject remuneration report as Althea is dealt ‘first strike’

by Steve Jones January 31, 2024July 11, 2024

Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix

by Steve Jones and Martin Lane January 31, 2024July 11, 2024

Administrator ponders offers for Bod assets ahead of report to creditors

by Steve Jones January 30, 2024July 16, 2024

Melodiol ‘evaluating proposal’ to sell ‘various core assets’

by Steve Jones January 17, 2024July 11, 2024

CanView tech provider walks away from Vitura after ASX firm raises ‘conduct’ issues

by Steve Jones January 17, 2024July 11, 2024

Hunt for Medlab buyer drew ‘bottom feeders’, says MD as plan unfolds to deliver shareholder return

by Steve Jones January 17, 2024July 11, 2024